EGFR and carcinoma: Therefore, we hypothesized that the acquisition of EGFR‐TKI resistance in carcinoma cells could alter the therapeutic efficacy of ICI through changing aspects of the TIME, such as the level of lymphocyte infiltration in NSCLC patients, based on the studies reported above.